Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | NRAS Q61K |
Therapy | Lifirafenib + Pimasertib |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61K | lung non-small cell carcinoma | sensitive | Lifirafenib + Pimasertib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Lifirafenib (BGB-283) and Pimasertib (MSC1936369B) synergistically inhibited proliferation of a non-small cell lung cancer cell line harboring NRAS Q61K in culture, and demonstrated improved efficacy over either agent alone (PMID: 32336014). | 32336014 |
PubMed Id | Reference Title | Details |
---|---|---|
(32336014) | RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors. | Full reference... |